Purpose The laser in glaucoma and ocular hypertension (LiGHT) trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open angle glaucoma (POAG) or ocular hypertension (OHT). Design LiGHT is a prospective unmasked, multicentre, pragmatic, randomised controlled trial (RCT). Participants 718 previously untreated patients with POAG or OHT were recruited at 6 UK centres between 2012 and 2014. Methods Patients were randomised to initial SLT followed by medical therapy or medical therapy without laser. Participants will be monitored for 3 years, according to routine clinical practice. The primary outcome is EQ-5D-5L. Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index (GUI), Glaucoma Symptom Scale, Glaucoma Quality of Life (GQL), pathway effectiveness, visual function, safety and concordance. results A total of 555 patients had POAG and 163 OHT; 518 patients had both eyes eligible. The mean age for patients with POAG was 64 years and for OHT 58 years. 70% of all participants were white. Median IOP for OHT eyes was 26 mm Hg and 23 mm Hg for POAG eyes. Median baseline visual field mean deviation was −0.81 dB for OHT eyes and −2.82 dB for POAG eyes. There was no difference between patients with POAG and patients with OHT on the EQ-5D-5DL; the difference between OHT and POAG on the GUI was −0.02 and 1.23 on the GQL. Conclusions The LiGHT trial is the first RCT to compare the two treatment options in a real-world setting. The baseline characteristics of the LiGHT cohort compare well with other landmark glaucoma studies. Trial registration number ISRCTN32038223, Preresults.
InTroDuCTIon
Glaucoma is recognised as the leading cause of irreversible blindness worldwide. 1 Intraocular pressure (IOP) is the only modifiable risk factor; laser and topical medication both effectively reduce IOP. [2] [3] [4] Topical medical treatment is associated with questionable long-term acceptability and impaired health-related quality of life (HRQL) due to considerable cost, side effects and numerous hospital visits. 5 The laser in glaucoma and ocular hypertension (LiGHT) trial compares HRQL in patients who started treatment using topical IOP lowering medication to that in patients who were treated with SLT first. LiGHT also compares the clinical and cost-effectiveness of the two pathways. The design of LiGHT has been described elsewhere. 6 Briefly, LiGHT is a multicentre, randomised clinical trial, unmasked to treatment allocation. Eligible patients with POAG or OHT were randomised to either SLT or medical therapy (drops) as first-line treatment. Patients with one or both eyes eligible were treated identically. All measurements influencing treatment escalation decisions were made by observers masked to treatment status. Target IOP, follow-up intervals and treatment escalation decisions were guided by custom-written decision support software using visual field, IOP and disc imaging information to avoid bias in clinical decision-making. Patients were followed up for 3 years.
MeThoDs
Eligible patients were identified at the National Health Service (NHS) clinics of six participating centres in the UK from October 2012 through to October 2014 (supplementary appendix 1). Patients had newly diagnosed, untreated POAG in one or both eyes (including normal tension glaucoma and pseudoexfoliative glaucoma) or OHT qualifying for treatment according to National Institute for Health and Clinical Excellence (NICE) guidelines, 7 open angles and for POAG visual field loss with mean deviation (VF MD) not worse than −12 dB in the better eye or −15 dB in the worse eye and corresponding damage to the optic nerve head. Patients were 18 years or older and able to understand English, had a visual acuity of 6/36 or better in the treated eye(s), no history of treatment for POAG or OHT and no previous intraocular surgery, except uncomplicated phacoemulsification at least 1 year before entering the trial. Patients were excluded if there were contraindications to SLT, they were unable to use topical medical therapy, they had visually significant cataract or were having treatment for another ophthalmic condition. A glaucoma subspecialist fellowship-trained consultant ophthalmologist's decision to initiate treatment was required for inclusion in the trial.
The IOP was measured with Goldman applanation tonometry, by experienced clinicians masked Clinical science to treatment allocation. The VF tests were performed with the Humphrey Field Analyser Mark II (SITA standard 24-2) (Carl Zeiss Meditec, Dublin, California, USA). Optic nerve head scans were obtained with the Heidelberg retina tomograph (HRT) (Heidelberg Engineering, Heidelberg, Germany). The refractive error was calculated as the spherical diopters measured with an autorefractor. General health information and medication were recorded based on the patients' reporting.
The study adheres to the tenets of the Declaration of Helsinki and had been granted ethical approval.
Disease classification
NICE recommended thresholds were used for disease classification and for initiating treatment. 7 For the purposes of disease classification 'per patient', participants were classified as having POAG in at least one eye, as this represents the pragmatic treatment in a clinical setting. Patients were classified as having OHT if at least one eye had OHT (but no POAG).
outcome measures
The primary outcome measure is HRQL measured using EQ-5D-5L 8 with utility scores calculated using the English time trade off value set. 9 Secondary outcome measures are treatment pathway healthcare resource use, cost and cost-effectiveness (Client Service Receipt Inventory' (CSRI)) questionnaire, 10 glaucoma specific treatment-related quality of life ((Glaucoma Utility Index (GUI)) 11 patient-reported disease and treatment-related symptoms (Glaucoma Symptom Scale (GSS)) 12 and visual function (Glaucoma Quality of Life-15 (GQL-15)), 13 objective measurements of pathway effectiveness for IOP lowering and visual function preservation, objective safety measures for each treatment pathway and concordance. Questionnaires are sent to patients at 6 monthly intervals.
statistical analysis
Summary measures for the baseline characteristics of the participating patients and eyes are presented as mean and SD for continuous variables with a symmetric distribution, medians and IQR for continuous, skewed variables and frequencies and percentages for categorical variables. Means and SD are also reported in some cases and for EQ-5D-5L and GUI to allow for comparisons with values reported in other studies. The difference in means and corresponding 95% CIs between OHT and POAG in EQ-5D-5L utility scores, GUI, GSS and GQL are generated using linear regression and bootstrapping with 1000 replications. These summaries are based on observed data only and the number of missing observations will be reported. Stata V.13.0 (StataCorp LP, Texas, USA) was used for the data analysis.
resulTs baseline patient characteristics
Seven hundred and eighteen patients were recruited: 301 patients (41.9%) had bilateral POAG and 161 (22.4%) had unilateral POAG (fellow eye healthy); 93 patients (13.0%) had POAG in one eye and OHT in the other eye; 124 patients (17.3%) had bilateral OHT and 39 patients (5.4%) had unilateral OHT. A total of 555 patients (77.2%) were classified as POAG and 163 patients (22.7%) were classified as OHT: 518 patients (72.1%) had both eyes eligible for the trial; 96 patients (13.4%) had only the right eye eligible and 104 patients (14.5%) had only the left eye eligible; 55% of the better eyes were right eyes. Table 1 summarises the baseline patient characteristics.
In both diagnostic groups, more male than female patients were recruited (POAG 55% males; OHT 58% males). The mean age for patients diagnosed with POAG was 64 years (SD=12 years) (median (IQR)=65 (56-73) and for OHT 58 years (SD=11 years) (median (IQR)=57 (50-65)). A total of 70% of all participants were white; black was the second largest ethnic group (20%). Thirty per cent of patients with POAG reported a family history of glaucoma, compared with 28% of patients with OHT. Systemic hypertension was noted in 34% of the patients with POAG and 37% of the patients with OHT. Use of systemic antihypertensive medication was noted in 35% of all patients, 27% were on statins and 11% were smokers.
baseline characteristics for eligible eyes
A total of 854 eyes (69%) were classified as POAG and 380 eyes (31%) were classified as OHT. The median baseline VF MD was −0.81 dB for OHT eyes (mean (SD)=−1.25 (2.05) dB) and −2.82 dB for POAG eyes (mean (SD)=3.81 (3.68) dB). The median IOP for OHT eyes was 26 mm Hg (mean (SD)=26.7 (3.5) mm Hg) and 23 mm Hg for POAG eyes (mean (SD)=23.5 (5.4) mm Hg). A total of 24% of the POAG eyes had a baseline IOP of 19 mm Hg or below. Median neuroretinal rim area was 1.25 mm 2 for OHT eyes and 1.04 mm 2 for POAG eyes. Median central corneal thickness (CCT) for OHT eyes was 557 µm (mean CCT (SD)=557 (39) μm) and for POAG eyes 549 µm (mean CCT (SD)=549 (36) μm). Glaucomatous eyes were more myopic and had worse VA than OHT eyes (table 2) .
baseline data of questionnaire survey
Patients with POAG scored a median of 0.94 on the EQ-5D-5DL (mean (SD)=0.92 (0.13)) and 0.90 on GUI (mean (SD)=0.89 (0.12)). On GSS, patients with POAG scored a median of 85 (mean (SD)=82.4 (16.7)) and 17 on GQL-15 (mean (SD)=19.1 (6.3)). Patients with OHT scored a median of 0.94 on the EQ-5D-5DL (mean (SD)=0.91 (0.14)) and 0.93 on GUI (mean (SD)=0.91 (0.1)). On GSS, patients with OHT scored a median of 85 (mean (SD)=82.3 (17.6)) and 16 on GQL-15 (mean (SD)=17.9 (5.4)) (table 3). There was no difference between patients with POAG and patients with OHT on the EQ-5D-5L (difference 0.00, 95% CI −0.02 to 0.03) and on the GSS (difference 0.08, 95% CI −2.91 to 3.07); the difference between OHT and POAG on the GUI was −0.02 (95% CI −0.04 to 0.001) and on the GQL difference 1.23 (95% CI 0.15 to 2.31).
DIsCussIon
The LiGHT trial is a multicentre RCT, comparing HRQL, clinical and cost-effectiveness and safety of SLT versus topical IOP lowering medication in treatment-naive patients with newly diagnosed POAG or OHT. LiGHT has an eye-specific target IOP and follows routine clinical practice, permitting any medication (apart from pilocarpine) and any treatment escalations, providing a realistic analysis of glaucoma and OHT management.
The higher black population in LiGHT (20%) compared with the United Kingdom Glaucoma Treatment Study (UKGTS) (5.2%) 14 is attributable to the high proportion recruited in ethnically diverse London (66.8%), similar to studies conducted in the USA, such as the Advanced Glaucoma Intervention Study (AGIS), 15 Collaborative Glaucoma Initial Glaucoma Treatment Study (CIGTS) 16 and Ocular Hypertension Treatment Study (OHTS), 17 with higher proportions of black participants (56.2%, 38.1%, 25%, respectively).
A total of 42% of the patients had bilateral POAG, a proportion lower than UKGTS (51.8%), but higher than the Early Manifest Glaucoma Trial (EMGT) (24% overall).
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Clinical characteristics
LiGHT patients diagnosed with POAG were slightly younger than the UKGTS cohort (mean 64.1 and 66 years, respectively). The EMGT recruited older newly diagnosed patients (median 65 years for LiGHT POAG and 68 years for EMGT), whereas CIGTS recruited younger patients (median 56 and 61 years for black and white patients, respectively). Age differences might reflect the differing proportion of black patients, in whom POAG is seen at a younger age. There were more male patients in the LiGHT POAG cohort (55%), as in the UKGTS (52.9%) and CIGTS (55%).
The LiGHT POAG cohort had overall higher IOPs than UKGTS (mean IOP 23.5 vs 19.5 mm Hg, respectively) and EMGT (median LiGHT 23 mm Hg vs EMGT 20.5 mm Hg); CIGTS reported distinctly higher IOPs (mean 27.6 mm Hg medicine group, 27.4 mm Hg surgery group). Nearly a quarter of POAG LiGHT eyes had a baseline IOP ≤19 mm Hg, fewer than in the EMGT (56.1%) and UKGTS (43%). Differences in mean presenting IOP between studies may reflect differences between referral patterns, with a more frequent rate of normal tension glaucoma diagnosis in some areas. (12) 58 (11) 64 (12) Ethnicity* Asian 51 (7) 8 (5) 43 (8) Black 146 (20) 45 (28) 101 (18) Whites 501 (70) 104 (64) 397 (71) Other 20 (3) 6 (4) 14 (3) General health Asthma 93 (13) 17 (10) 76 (14) Hypertension 251 (35) 60 (37) 191 (34) Diabetes 82 (11) 24 (15) 58 (10) Angina 21 (3) 4 (2) 17 (3) Cardiac arrhythmia 37 (5) 4 (2) 33 (6) Ischaemic heart disease 20 (3) 3 (2) 17 (3) Cerebrovascular accident/stroke 14 (2) 2 (1) 12 (2) Migraines 94 (13) 16 (10) 78 (14) Peripheral vasospastic symptoms 63 (9) 7 (4) 56 (10) Blood loss/transfusion 76 (11) 14 (9) 62 (11) Family ocular history of glaucoma † (first-degree relative) 214 (30) 46 (28) 168 (30) *'Asian' ethnicity refers to Indian, Pakistani, Bangladeshi and any other Asian background; 'Black' ethnicity refers to Caribbean, African and any other black background and 'Other' ethnicity refers to Chinese and any other ethnic groups. †n=717.
Table 2
One thousand two hundred and thirty-four eyes of 718 patients were treated in the study 
Clinical science
LiGHT patients with POAG appeared to have early stage disease similar to UKGTS (median VF MD −2.8 dB for LiGHT, UKGTS −2.9 dB) and less severe than EMGT (median VF MD −4.7 dB) and CIGTS (−5.5 dB), possibly reflecting different referral thresholds or access to screening. Similarly to UKGTS and CIGTS, 30% of LiGHT patients with POAG reported having a family history of POAG.
Systemic hypertension was noted in 34% of the LiGHT patients with POAG, similar to EMGT (38%) and CIGTS (37% overall), but lower than UKGTS (57.8%) and AGIS (overall 46.78%). Diabetes was recorded for 11% of the LiGHT patients, similar to the UKGTS (10.5%), but different to studies conducted in other countries (AGIS 20.3%, EMGT 4%). A total of 3% of LiGHT patients with POAG reported ischaemic heart disease (UKGTS 5.4%, EMGT 6%). Almost a quarter of the patients with POAG reported symptoms suggestive of vasospastic conditions (LiGHT POAG 10%, EMGT 9%) or migraines (LiGHT POAG 14%, EMGT 10%), compared with almost half of the UKGTS patients (overall 47.4%).
The LiGHT OHT cohort was on average slightly older than the OHTS cohort (mean LiGHT 57.7, OHTS 55.4 years), but similar to the European Glaucoma Prevention Study (EGPS) cohort. 19 The LiGHT OHT cohort also had more males (58%) than females, unlike OHTS and EGPS.
OHT eyes of the LiGHT cohort had a mean IOP of 26.7 mm Hg, higher than that reported by OHTS (24.9 mm Hg) and EGPS (23.6 mm Hg). LiGHT OHT eyes had worse VF MD (mean −1.25 dB) than the OHTS cohort (0.24 dB) and the EGPS cohort (0.18 dB). CCT in the LiGHT OHT cohort was lower than the OHTS cohort (mean 557 vs 573 µm, respectively). These differences could arise from differences between NICE treatment thresholds and OHTS entry criteria.
Of the LiGHT patients with OHT, 28% reported a family history of glaucoma, in contrast to 44% of the OHTS cohort. The prevalence of systemic hypertension and diabetes in the LiGHT OHT cohort were similar to OHTS.
The mean IOP was lower in POAG eyes compared with OHT eyes (23.5 vs 26.7 mm Hg, respectively). OHT eyes had overall thicker corneas compared with POAG eyes (557 vs 549 µm, respectively). More patients with POAG reported symptoms suggestive of vasospastic conditions compared with patients with OHT.
heAlTh-relATeD quAlITy of lIfe
The EQ-5D-5L was developed to overcome some of the ceiling effects commonly seen in the EQ-5D-3L, having more discriminatory power and less of a ceiling effect. 20 This is the only study, after EAGLE, to report the results of the EQ-5D-5L in a UK population with OHT or POAG.
The mean EQ-5D-5L score of 0.92 for the LiGHT POAG cohort is higher than the UK average EQ-5D-3L score of 0.799 to 0.779. 21 LiGHT patients diagnosed with POAG had lower scores than newly diagnosed EAGLE patients, despite the previous exposure of the latter cohort to IOP lowering treatment. 22 The utility scores of the LiGHT POAG cohort are higher than other cohorts of patients with POAG, although these are for older patients with more advanced disease or under various treatment modalities. 23 Mean GUI scores of the POAG LiGHT cohort (0.89) were not substantially different from the EAGLE study (lens extraction 0.897, peripheral iridotomy 0.921). 22 LiGHT patients with POAG scored higher in the GSS than patients in other studies. 12 LiGHT patients with POAG showed better QoL compared with other POAG cohorts as measured with the GQL-15 and scored similarly to patients with normal VF. 24 HRQL has not been studied extensively in patients with OHT. In OHTS, the recruited patients showed better HRQL at baseline than age-matched and gender-matched population-based norms, which was attributed to the cohort's high educational and/or socioeconomic status. The LiGHT OHT cohort shows higher utility scores, measured with the EQ-5D-5DL and GQL-15, when compared with a different cohort of untreated OHT. 25 There was no difference between patients with POAG and patients with OHT on EQ-5D-5L and the GSS, but GUI, a preference-based tool to measure disutility directly related to glaucoma used by the EAGLE trial, and GQL were both better at discriminating between OHT and POAG, even at an early disease stage, suggesting greater sensitivity in this setting. 
